Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$14.09 - $19.87 $2.01 Million - $2.84 Million
142,766 Added 149.4%
238,327 $3.78 Million
Q2 2023

Aug 09, 2023

SELL
$3.75 - $20.05 $463,657 - $2.48 Million
-123,642 Reduced 56.41%
95,561 $1.8 Million
Q1 2023

May 12, 2023

BUY
$3.67 - $4.92 $294,132 - $394,313
80,145 Added 57.63%
219,203 $841,000
Q4 2022

Feb 09, 2023

BUY
$4.55 - $6.31 $337,418 - $467,936
74,158 Added 114.27%
139,058 $689,000
Q3 2022

Nov 09, 2022

SELL
$4.48 - $6.47 $70,519 - $101,844
-15,741 Reduced 19.52%
64,900 $310,000
Q2 2022

Aug 11, 2022

SELL
$3.15 - $5.76 $58,511 - $106,992
-18,575 Reduced 18.72%
80,641 $363,000
Q1 2022

May 12, 2022

BUY
$4.26 - $7.48 $227,002 - $398,586
53,287 Added 116.02%
99,216 $472,000
Q4 2021

Feb 11, 2022

SELL
$4.75 - $7.5 $131,584 - $207,765
-27,702 Reduced 37.62%
45,929 $341,000
Q3 2021

Nov 12, 2021

BUY
$5.02 - $6.59 $302,013 - $396,467
60,162 Added 446.67%
73,631 $417,000
Q2 2021

Aug 10, 2021

BUY
$5.79 - $8.6 $77,985 - $115,833
13,469 New
13,469 $89,000
Q1 2021

May 12, 2021

SELL
$6.5 - $10.53 $349,134 - $565,597
-53,713 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$3.7 - $7.66 $198,738 - $411,441
53,713 New
53,713 $346,000
Q3 2020

Nov 12, 2020

SELL
$3.45 - $4.89 $90,289 - $127,976
-26,171 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$3.32 - $5.34 $67,346 - $108,321
20,285 Added 344.63%
26,171 $120,000
Q1 2020

May 13, 2020

BUY
$2.12 - $6.8 $12,478 - $40,024
5,886 New
5,886 $20,000
Q2 2019

Aug 09, 2019

SELL
$1.8 - $3.3 $186,651 - $342,193
-103,695 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$2.41 - $5.91 $1,024 - $2,511
-425 Reduced 0.41%
103,695 $281,000
Q4 2018

Feb 06, 2019

BUY
$3.94 - $9.7 $321,472 - $791,442
81,592 Added 362.18%
104,120 $500,000
Q3 2018

Nov 08, 2018

SELL
$8.6 - $11.26 $618,159 - $809,357
-71,879 Reduced 76.14%
22,528 $213,000
Q2 2018

Aug 14, 2018

BUY
$9.52 - $12.15 $898,754 - $1.15 Million
94,407 New
94,407 $919,000
Q1 2018

May 11, 2018

SELL
$6.7 - $12.95 $61,841 - $119,528
-9,230 Closed
0 $0
Q4 2017

Feb 09, 2018

SELL
$5.07 - $7.92 $60,855 - $95,063
-12,003 Reduced 56.53%
9,230 $59,000
Q3 2017

Nov 15, 2017

BUY
$5.4 - $8.47 $114,658 - $179,843
21,233
21,233 $162,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.